Drugs / STAR-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07431216 | May 2026 → May 2027 expected | glioblastoma | Starlight Therapeutics Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-05-15 | Lantern Pharma Inc. | Regulatory Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates lanternpharma.com ↗
Pediatric brain cancer IND cleared by FDA for enrollment for Lantern Pharma subsidiary, Starlight Therapeutics |
| 2026-03-27 | Lantern Pharma Inc. | Regulatory Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001 lanternpharma.com ↗
Lantern Pharma Inc. (NASDAQ: LTRN) and its CNS-oncology focused wholly owned subsidiary Starlight Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for STAR-001 in a planned Phase 1 pediatric clinical trial (IND No. 179145). |
| 2025-08-06 | Lantern Pharma Inc. | Regulatory Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial lanternpharma.com ↗ |
| 2024-11-26 | Lantern Pharma Inc. | Results Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality lanternpharma.com ↗
Preclinical data, including in previously published research by Lantern Pharma, demonstrates up to 6-fold increase in GBM cell sensitivity when LP-184 is combined with spironolactone. |
| 2024-10-15 | Lantern Pharma Inc. | Regulatory Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA lanternpharma.com ↗
today announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Glioblastoma. |
All press releases naming this drug 7 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STAR-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07431216 ↗ |
| Known as | LP-184 | “STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle.” NCT07431216 ↗ |
| Route | Intravenous | “via IV infusion” NCT07431216 ↗ |